A

Amgen

Makes biotech medicines for serious illnesses

Senior Validation Engineer 1

Full-TimeUpdated on 10/15/2026
No salary listed
Senior
Bachelor's, Master's, PhD, Associate's
Singapore
In Person
Biology & BiotechRegulatory & Quality (Life Sciences)

About the job

Requirements
  • A doctorate degree.
  • A master's degree in engineering and 2 years of experience in a pharmaceutical company or GMP environment, or a bachelor's degree in engineering and 4 years of experience in a pharmaceutical company or GMP environment, or a diploma in engineering and 8 years of experience in a pharmaceutical company or GMP environment.
  • Demonstrated proficiency in written and verbal communication, including technical writing and presentations, and the ability to communicate and collaborate effectively with technical and senior management staff.
  • Experience reviewing and approving validation protocols and reports supporting facility or equipment commissioning, qualification, and change management.
  • Experience technically executing validation tasks associated with cleaning validation, steaming validation (including autoclaves), and controlled temperature chambers (CTC).
  • Experience maintaining the validated state through continued verification.
  • Experience resolving complex validation-related investigations and using root cause analysis tools.
  • Experience supporting regulatory submissions, responding to submission questions, pre-approval and biennial inspections, and observational response plans, including explaining validation matters to auditors.
  • Experience training and coaching junior engineers and managing validation resources to meet schedules.
  • Ability to work independently in a fast-paced, dynamic work environment.
  • Time management, attention to detail, and ability to multitask across concurrent projects.
Responsibilities
  • Provide technical support and lead a team of validation engineers providing support for commissioning, qualification, cleaning validation, and validation lifecycle maintenance in ASM.
  • Establish validation strategies and procedures aligned with Amgen operating standards and regulatory expectations.
  • Coordinate actions with Manufacturing, Engineering, Quality, Supply Chain, and Process Development to meet Amgen validation requirements.
  • Provide subject matter expert support and represent validation for filings, audits, and regulatory inspections.
  • Interact with Amgen’s corporate validation network to influence strategic management of validation programs.
  • Own or provide subject matter expertise for standard operating procedures, deviations, corrective and preventive actions, validation schedules, and change-control validation impact assessments.
  • Escalate significant validation-related issues to operations management in a timely manner.
  • Lead and support site- and network-wide validation-driven continuous improvement initiatives and activities.
  • Mentor and coach cross-functional team members on validation technical knowledge.
  • Drive Operational Excellence initiatives within the validation workspace.
  • Deliver cleaning validation work, including generating, reviewing, and approving cleaning-related documents such as cleaning strategies and methodologies, cleaning characterization and inactivation reports, and acceptance-limits reports for new product introductions.
  • Execute, lead, and drive cleaning development, verification, and validation activities, including change control, training, and generation, review, and approval of protocols and reports.
  • Oversee validation tasks and advise clients on equipment validation for manufacturing process equipment, supply-chain facilities, and analytical laboratories.
  • Technically execute validation tasks associated with controlled temperature chambers (CTC), including commercial off-the-shelf units and potentially more complex validations.
  • Collaborate with project leads accountable for validation deliverable milestones related to commissioning and qualification, across projects ranging from equipment upgrades to large-scale capital projects and facility construction.
  • Maintain the site validation master plan and routinely monitor validation status and regulatory compliance of equipment and systems.
Desired Qualifications
  • Extensive experience in equipment qualification and cleaning validation, including establishing validation strategies and procedures, for a pharmaceutical facility.
  • Strong knowledge and understanding of small-molecule cleaning and manufacturing unit operations.

About the company

Amgen develops and makes biologic medicines, which are drugs built from proteins and antibodies grown in living cells, for serious conditions such as heart disease, cancer, and bone loss. Its anemia drug Epogen, approved in 1989, became one of the biotechnology industry's first blockbuster medicines. Amgen grows these drugs in large tanks called bioreactors, and its products include the cholesterol drug Repatha, the bone-building drug Evenity, and the severe asthma drug Tezspire. It earns money by selling these medicines, mostly through large drug wholesalers that supply hospitals and pharmacies. Amgen was founded in 1980 and is based in Thousand Oaks, California.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Growth is broad-based: 22 products grew at least 10%, lifting June 2026 quarter revenue 10% to $10.1 billion.
  • Stock grants gained value: Amgen shares rose 27% from January to October 9, 2026, versus 10% for rival Eli Lilly.
  • Many U.S. roles are remote: 145 of Amgen's 615 U.S. job openings in October 2026 were fully remote.

What critics are saying

  • Its 2025 best seller is shrinking: cheaper copies cut bone drug Prolia's sales 32% in the June 2026 quarter.
  • MariTide, Amgen's obesity bet, faces a giant: Lilly's Mounjaro and Zepbound outsold all of Amgen in the June 2026 quarter.
  • Most tech openings are in India: 156 of Amgen's 210 information systems jobs in October 2026 were in Hyderabad.

What makes Amgen unique

  • It copies rivals' blockbusters too: Pavblu, its version of Regeneron's eye drug Eylea, sold $700 million in 2025.
  • Amgen hunts drug targets in a nation's DNA: its Icelandic unit deCODE has genetic data on two-thirds of Iceland's adults.
  • Amgen opened a U.S. cancer-drug class: Blincyto, approved in 2014, was the first to tether immune cells to cancer.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Oct 8th, 2026
Amgen invests $2.6B in manufacturing for MariTide obesity drug ahead of Phase III results

Amgen is testing MariTide, an experimental obesity drug designed to be dosed monthly or less frequently. The therapy has advanced into late-stage Phase III trials, with nine studies currently running and three more planned. Executives reported strong enrolment during the company's second-quarter 2026 earnings call on 4 August 2026. Amgen expects capital spending of about $2.6 billion in 2026, partly to scale manufacturing capacity for MariTide's eventual launch. The company is investing across its US manufacturing sites in North Carolina, Ohio, and Puerto Rico. Amgen stock has returned 44% over the past twelve months, outpacing the S&P 500's 17.1% gain. The company reported $38.1 billion in revenue over the last twelve months, up from $34.9 billion a year earlier.

Yahoo Finance
Sep 29th, 2026
Amgen lifts dividend 6%, but eroding Prolia and Enbrel sales shift focus to MariTide Phase 3

Amgen raised its quarterly dividend 6% to $2.52 per share, marking its 14th consecutive annual increase since starting payouts in 2011. The biotech now pays $10.08 annually, yielding 2.36% at current share prices of $418.13. The dividend appears well covered. Amgen generated $8.1 billion in free cash flow in 2025 against $5.1 billion in dividend payments. Second quarter 2026 free cash flow reached $3.5 billion whilst dividends consumed $1.4 billion. However, biosimilar competition is eroding legacy revenue. Prolia and XGEVA sales dropped 33% whilst Enbrel fell 37%. The company carries $57 billion in debt. Future dividend growth may hinge on Phase 3 results for MariTide, Amgen's obesity candidate. The company follows a steady raise pattern similar to Johnson & Johnson, contrasting with Pfizer's post-COVID payout struggles.

Yahoo Finance
Sep 26th, 2026
Vertex and Amgen deliver promising pipeline updates as both outperform market

Vertex Pharmaceuticals reported strong second-quarter results, with revenue rising 12% year-over-year to $3.33 billion and earnings per share climbing 8% to $4.31. The company posted positive Phase 2b results for inaxaplin, an experimental treatment for APOL1-mediated kidney disease, showing it reduced proteinuria in patients with modest protein levels and those with type 2 diabetes. Vertex expects approval for povetacicept, a treatment for IgA nephropathy, by November. The company continues diversifying beyond its core cystic fibrosis franchise, which provides predictable revenue as patients require lifelong treatment. Meanwhile, Amgen has also outperformed the broader market this year, though specific recent developments were not detailed in the source material.

Yahoo Finance
Sep 11th, 2026
Revolution Medicines' first pancreatic cancer therapy approval challenges Amgen's biotech dominance

Revolution Medicines received FDA approval for daraxonrasib, the first targeted therapy for metastatic pancreatic cancer, after clinical data showed it reduced death risk by more than half. The company is clinical-stage with no current revenue and posted a $1.1 billion net loss in FY 2025. Amgen reported FY 2025 revenue of $36.7 billion, up 9.9% year-over-year, with net income of $7.7 billion and a 21% net margin. Free cash flow reached $8.1 billion. The company carries a debt-to-equity ratio of 6.3x. Revolution Medicines maintains a 0.1x debt-to-equity ratio and 9.5x current ratio but recorded negative free cash flow of $913.7 million. The company's pipeline targets RAS-driven tumours including lung cancer. A partnership with Royalty Pharma provides funding for development. Both companies face distinct risks: Amgen confronts pricing pressures and biosimilar competition, whilst Revolution Medicines carries clinical trial failure risks and competes against larger pharmaceutical firms.

Yahoo Finance
Sep 11th, 2026
Amgen vs CRISPR Therapeutics: Which healthcare stock offers better value in 2026?

Amgen reported revenue of $36.7 billion in FY 2025, up 9.9% year-over-year, with net income of $7.7 billion and a 21% net margin. The biotech giant maintains a debt-to-equity ratio of 6.3x and generated $8.1 billion in free cash flow. CRISPR Therapeutics, meanwhile, saw revenue fall 90% to $3.5 million in FY 2025, posting a net loss of $581.6 million. The gene-editing firm burns $345.9 million in cash but holds a strong current ratio of 13.3x. Its CASGEVY therapy for sickle cell disease has gained approval in the US, UK, and EU, with Vertex handling commercialisation under a 60-40 revenue split. Amgen faces pricing pressure from the Inflation Reduction Act and biosimilar competition. CRISPR Therapeutics carries clinical execution risk and ongoing intellectual property disputes.